(Q37212678)

English

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

scientific article published on 28 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis (English)

1 reference

Europe PubMed Central

19 August 2017

chronic phase chronic myelogenous leukemia

0 references

1 reference

based on heuristic

inferred from title

Catherine Roche-Lestienne

14

object named as

Catherine Roche-Lestienne

0 references

Véronique Maguer-Satta

object named as

Véronique Maguer-Satta

19

0 references

Simona Soverini

object named as

Simona Soverini

3

0 references

Andreas Hochhaus

object named as

Andreas Hochhaus

6

0 references

Jorge Eduardo Cortes

9

object named as

Jorge Cortes

1 reference

Europe PubMed Central

19 August 2017

Giovanni Martinelli

4

object named as

Giovanni Martinelli

1 reference

Europe PubMed Central

19 August 2017

Jane F Apperley

22

object named as

Jane F Apperley

1 reference

Europe PubMed Central

19 August 2017

Francois-Xavier Mahon

23

object named as

François-Xavier Mahon

1 reference

Europe PubMed Central

19 August 2017

11

object named as

Charles Chuah

1 reference

Europe PubMed Central

19 August 2017

7

object named as

Inge H Dufva

1 reference

Europe PubMed Central

19 August 2017

Mauricette Michallet

20

object named as

Mauricette Michallet

1 reference

Europe PubMed Central

19 August 2017

Hélène Labussière-Wallet

12

object named as

Hélène Labussière

1 reference

Europe PubMed Central

19 August 2017

Stéphane Morisset

13

object named as

Stéphane Morisset

1 reference

Europe PubMed Central

19 August 2017

Sandrine Hayette

16

object named as

Sandrine Hayette

1 reference

Europe PubMed Central

19 August 2017

17

object named as

Senaka Peter

1 reference

Europe PubMed Central

19 August 2017

Franck E Nicolini

1

object named as

Franck E Nicolini

1 reference

Europe PubMed Central

19 August 2017

author name string

Amr R Ibrahim

2

1 reference

Europe PubMed Central

19 August 2017

Martin C Müller

5

1 reference

Europe PubMed Central

19 August 2017

Dong-Wook Kim

8

1 reference

Europe PubMed Central

19 August 2017

Michael J Mauro

10

1 reference

Europe PubMed Central

19 August 2017

Eric Lippert

15

1 reference

Europe PubMed Central

19 August 2017

Wei Zhou

18

1 reference

Europe PubMed Central

19 August 2017

John Goldman

21

1 reference

Europe PubMed Central

19 August 2017

David Marin

24

1 reference

Europe PubMed Central

19 August 2017

Gabriel Etienne

25

1 reference

Europe PubMed Central

19 August 2017

publication date

28 May 2013

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

98

1 reference

Europe PubMed Central

19 August 2017

10

1 reference

Europe PubMed Central

19 August 2017

1510-1516

1 reference

Europe PubMed Central

19 August 2017

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

6 September 2017

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

6 September 2017

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

6 September 2017

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

6 September 2017

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

6 September 2017

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

6 September 2017

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

6 September 2017

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

6 September 2017

Activation of tyrosine kinases by mutation of the gatekeeper threonine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

6 September 2017

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

6 September 2017

Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

6 September 2017

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

6 September 2017

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

6 September 2017

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

6 September 2017

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

14 September 2017

The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

26 June 2018

Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

3 September 2018

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

3 September 2018

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

3 September 2018

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

3 September 2018

A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

3 September 2018

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

3 September 2018

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

20 October 2018

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789454

4 December 2018

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23716543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23716543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeted therapy and the T315I mutation in Philadelphia-positive leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/23716543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23716543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23716543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2012.080234

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37212678&oldid=1747739123"